Photo by lcma1028 from unsplash
Chronic hepatitis C virus infection is one of the leading causes of slowly progressive hepatic fibrosis, which, if untreated, leads to cirrhosis, hepatic failure, and increased risk of death. In… Click to show full abstract
Chronic hepatitis C virus infection is one of the leading causes of slowly progressive hepatic fibrosis, which, if untreated, leads to cirrhosis, hepatic failure, and increased risk of death. In HCV infected patients, compared to earlier stages of fibrosis, cirrhosis is associated with less effective IFN-based treatment and a higher risk of complications. Since 2015 an interferon free therapy drug program (B.71) is available in Poland for patients with chronic HCV, currently including five regimens: • ombitasvir / paritaprevir / ritonavir + dasabuvir (OBV/PTV/r + DSV), • daklatasvir + asunaprevir, • sofosbuvir, • sofosbuvir / ledipasvir, • grazoprevir / elbasvir.